Core Insights - Flow Capital Corp. reported a significant increase in loan interest revenue and recurring free cash flow for the second quarter of 2025, indicating strong business performance and effective management execution [1][4]. Financial Performance Highlights Three Months Ended June 30, 2025, Compared to Three Months Ended June 30, 2024 - Loan interest and royalty revenue increased by 54% to $3.2 million from $2.1 million [7]. - Recurring free cash flow rose by 212% to $884,129 from $283,036 [7]. - Total revenues decreased to $1.4 million from $1.8 million [6]. - Net income showed a loss of $1.5 million compared to a profit of $190,000 [6]. Six Months Ended June 30, 2025, Compared to Six Months Ended June 30, 2024 - Loan interest and royalty revenue increased by 49% to $6.1 million from $4.1 million [7]. - Recurring free cash flow increased by 148% to $1.7 million from $698,887 [7]. - Total revenues increased to $3.9 million from $3.7 million [6]. - Net income showed a loss of $1.0 million compared to a profit of $910,000 [6]. Investment and Growth Metrics - Total investments value increased by 39% to $72.2 million from $52.0 million [7]. - New investments amounted to $16.3 million compared to $9.3 million in the previous year [7]. - The company has consistently generated positive free cash flow over the last eight quarters, reflecting the strength of its business model [4].

Group 1 - McKinley Acquisition Corporation closed its initial public offering (IPO) of 15,000,000 units, priced at $10.00 per unit, resulting in gross proceeds of $150,000,000 [1][3] - The units are listed on The Nasdaq Global Market under the symbol "MKLYU", with each unit consisting of one Class A ordinary share and one right [2] - The proceeds from the IPO and a simultaneous private placement were placed in trust, with an audited balance sheet to be included in a Current Report on Form 8-K [3] Group 2 - Clear Street LLC acted as the sole book-running manager for the offering, while Brookline Capital Markets served as co-manager [4] - The underwriters have been granted a 45-day option to purchase up to 2,250,000 additional units at the initial public offering price to cover over-allotments [4] - A registration statement for these securities has been declared effective by the U.S. Securities and Exchange Commission (SEC) [5]

Core Points - Enovix Corporation's common stock has traded above $10.50 for 17 consecutive trading days since the distribution of warrants, with the current closing price at $10.98 per share and the warrants being $2.23 in-the-money based on an exercise price of $8.75 [1][3] - The warrants could expire early if the stock trades at or above $10.50 for 20 out of 30 trading days, with the earliest expiration date being August 19, 2025 [2] - Approximately 7.8 million warrants have been exercised, generating about $68.5 million in gross proceeds for the company [3] Warrant Exercise Process - The company plans to implement a process for warrant holders to cash exercise their warrants using a Notice of Guaranteed Delivery, requiring submission and payment before the expiration date [4] - Warrant holders are encouraged to act promptly as processing procedures may vary by broker [4] Company Overview - Enovix is a leader in advanced lithium-ion battery technology, focusing on silicon-anode batteries designed for various applications, including wearable electronics and electric vehicles [7] - The company is headquartered in Silicon Valley and has facilities in India, South Korea, and Malaysia [8]

Core Insights - Optiva Inc. reported its second quarter financial results for the period ending June 30, 2025, highlighting continued growth in bookings and customer acquisition [2][3]. Financial Performance - Revenue for Q2 2025 was $10.3 million, a decrease from $11.4 million in Q2 2024 [11][14]. - Total Contract Value (TCV) bookings for Q2 2025 reached $26.6 million, with a trailing twelve months TCV of $64.3 million [8][9]. - The gross margin for Q2 2025 was 49%, down from 56% in the same period last year, primarily due to lower high-margin support and subscription revenue [14]. - The adjusted EBITDA loss for Q2 2025 was $1.6 million, slightly improved from a loss of $1.7 million in Q2 2024 [11][14]. - The net loss for Q2 2025 was $4.4 million, compared to a net loss of $5.6 million in Q2 2024 [11][14]. Customer Acquisition and Strategic Developments - Optiva secured two new customers in Q2 2025, including a Tier 1 European mobile virtual network operator (MVNO) and a Tier 1 European telecom, bringing the total new customers to 13 over the past two years [3][9]. - A key existing customer, Digitel, renewed its BSS platform support agreement for an additional three years [9]. - Optiva was recognized as a finalist for the Most Innovative Telco AI/ML Product or Solution for the Leading Lights 2025 Awards [10]. Cash Position and Operational Updates - The company ended Q2 2025 with approximately $12.9 million in cash, sufficient to meet working capital commitments for the foreseeable future [5][14]. - Optiva has entered into a 45-day support agreement with 85% of noteholders to negotiate a strategic transaction, with expectations of reaching a binding agreement before the end of the forbearance period [4][19].

Core Insights - Binah Capital Group reported a 2% year-over-year increase in total revenue, reaching $42 million for the quarter ended June 30, 2025 [1][8] - The company's assets under management (AuM) grew by 11% year-over-year to $28 billion [1][8] - Binah experienced a net loss of $0.7 million, which is comparable to the prior year [1][8] - EBITDA increased to $1.0 million from $0.6 million in the prior year [1][8] Financial Performance - Total revenue for the second quarter increased by 2% year-over-year to $42 million [1][8] - Gross profit rose by 21% to $8.8 million, compared to $7.3 million in the prior-year period [8] - Total operating expenses remained consistent at $42 million compared to the prior-year period [8] - The company had cash and cash equivalents of $8.2 million and long-term debt of $18.6 million as of June 30, 2025 [5] Management Commentary - The CEO of Binah Capital expressed satisfaction with the company's performance, highlighting the advisor-centric platform and disciplined execution of strategy [2] - The management believes that their differentiated business model positions them well to capture future growth opportunities and create long-term shareholder value [2] Company Overview - Binah Capital Group operates a network of firms that empower independent financial advisors, specializing in brokerage, advisory, and insurance solutions [7] - The company aims to provide innovative solutions and resources to support advisors in navigating the complex financial landscape [7]

Core Viewpoint - BUUU Group Limited, a Hong Kong-based MICE solutions provider, has announced the pricing of its initial public offering (IPO) of 1,500,000 Class A ordinary shares at $4.00 per share, aiming to raise $6 million in gross proceeds [1][3]. Offering Details - The Class A Ordinary Shares are set to begin trading on the Nasdaq Capital Market under the symbol "BUUU" on August 14, 2025, with the offering expected to close on August 15, 2025, pending customary closing conditions [2]. - The company has granted underwriters a 45-day option to purchase an additional 225,000 Class A Ordinary Shares, which could increase gross proceeds to $6.90 million if fully exercised [3]. Use of Proceeds - The net proceeds from the offering will be utilized for enhancing brand recognition, strengthening marketing initiatives, expanding service offerings, integrating advanced technologies, and entering the U.S. and Southeast Asia markets, along with general corporate purposes [4]. Company Background - BUUU Group Limited is a premier MICE solutions provider with a comprehensive portfolio that includes event management and stage production, serving a diverse clientele such as public institutions and established brands [8].

Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) is pleased to announce its financial results for the three months ended June 30, 2025 (the “quarter”) and the six months ended June 30, 2025 (“YTD”). On May 5, 2025, the Fund entered into a non-binding letter of intent to which one or more affiliates of Fairfax Financial Holdings Limited (“Fairfax”) will acquire a ...

Core Viewpoint - BioSig Technologies, Inc. has announced its intention to offer shares of common stock through an underwritten public offering, following its recent merger with Streamex Exchange Corporation [1] Group 1: Offering Details - The offering will include shares of common stock or pre-funded warrants, with the completion subject to market conditions [1] - The net proceeds from the offering are intended for purchasing gold bullion, working capital, and general corporate purposes [1] - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, declared effective by the SEC on December 17, 2024 [3] - A preliminary prospectus supplement will be filed with the SEC, and interested parties are encouraged to read the documents for more information [3] Group 3: Company Background - BioSig Technologies is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6] - The PURE EP™ Platform developed by the company allows for real-time acquisition of raw signal data, enhancing procedural success in ablation treatments [7] - Streamex, a wholly owned subsidiary of BioSig, focuses on gold tokenization and building infrastructure for the gold market [5]

Core Insights - The company is making significant progress in its clinical operations and pipeline, particularly with govorestat for the treatment of CMT-SORD, and is preparing for a meeting with the FDA in Q3 2025 regarding a potential NDA submission [2][3] - A new sponsored Urine Sorbitol Assay has been launched to aid in the identification of patients with CMT-SORD, which is available at no cost to healthcare providers [3] - The company presented full 12-month clinical results from the INSPIRE Phase 2/3 trial of govorestat, showing slowed disease progression and statistically significant improvements in key secondary endpoints [3] CMT-SORD - A meeting with the FDA is scheduled to discuss the NDA submission strategy for govorestat, focusing on its treatment for CMT-SORD [3] - The company launched a Urine Sorbitol Assay to help healthcare providers identify suspected cases of CMT-SORD, removing barriers to diagnosis and treatment [3] - Full clinical results from the INSPIRE trial indicated that govorestat is generally safe and well-tolerated, with significant improvements in various health metrics [3] Classic Galactosemia - The company is reviewing its development program for govorestat in Classic Galactosemia, including responses to the Complete Response Letter from the FDA [4] PMM2-CDG - Results from an ongoing trial of govorestat for PMM2-CDG will be presented at the 2025 ASHG Annual Meeting, highlighting the drug's potential in treating this ultra-rare disease [5] Corporate Developments - The company entered into an out-licensing agreement with Biossil, Inc. for AT-001, gaining upfront payment and potential future royalties [9] - Key leadership changes were made, promoting Evan Bailey, M.D., to Chief Medical Officer and Dottie Caplan to Executive Vice President [9] Financial Results - As of June 30, 2025, cash and cash equivalents totaled $30.4 million, down from $79.4 million at the end of 2024 [7] - Research and development expenses for Q2 2025 were $9.9 million, slightly down from $10.0 million in Q2 2024 [7] - General and administrative expenses increased to $13.2 million in Q2 2025 from $10.6 million in Q2 2024, contributing to a net loss of $21.3 million for the quarter [7]

Core Insights - Mobix Labs achieved record adjusted gross margins of 60.6%, significantly up from 42.7% in the previous quarter and 40.3% year-over-year, indicating a strong shift towards higher-margin products and improved operational efficiency [5][11] - The company reported adjusted gross profit of $1.42 million for Q3 2025, reflecting a 32.7% increase from $1.07 million in the prior quarter and a 71.1% increase from $0.83 million year-over-year [5][11] - Year-over-year revenue growth reached $2.35 million, a 14.2% increase compared to $2.06 million in Q3 2024, demonstrating strong demand despite shipment timing variances [5][11] - The adjusted loss from operations improved to $1.17 million, a 64.2% reduction from the $3.27 million loss in the prior quarter [5][11] - For the first nine months of fiscal 2025, adjusted gross profit surged to $4.21 million, up 239.5% from $1.24 million in the same period last year, with adjusted gross margin expanding to 52.4% from 35.6% [5][11] Recent Business Highlights - The integration of RaGE Systems is enabling Mobix Labs to deliver faster, turnkey solutions, enhancing its position in aerospace and defense markets [5] - The company has expanded its relationships with top-tier defense contractors, positioning itself for multi-year program opportunities [5] - Mobix Labs announced an unsolicited proposal to acquire Peraso, Inc. at a 20% premium to its 30-day average share price, indicating a strategic commitment to market expansion and revenue growth [5] - The ongoing focus on expanding product offerings in RF/mmWave, EMI filtering, and next-generation connectivity is creating a robust pipeline for high-margin solutions in emerging 5G, aerospace, and defense applications [5]